Potassium

Identification

Name
Potassium
Accession Number
DB01345
Type
Small Molecule
Groups
Approved, Investigational
Description

Potassium is the major cation (positive ion) inside animal cells, while sodium is the major cation outside animal cells. The concentration differences of these charged particles causes a difference in electric potential between the inside and outside of cells, known as the membrane potential. The balance between potassium and sodium is maintained by ion pumps in the cell membrane. The cell membrane potential created by potassium and sodium ions allows the cell generate an action potential—a "spike" of electrical discharge. The ability of cells to produce electrical discharge is critical for body functions such as neurotransmission, muscle contraction, and heart function. Potassium is also an essential mineral needed to regulate water balance, blood pressure and levels of acidity.

Structure
Thumb
Synonyms
  • K
  • Kalium
Product Ingredients
IngredientUNIICASInChI Key
Potassium acetateM911911U02127-08-2SCVFZCLFOSHCOH-UHFFFAOYSA-M
Potassium sulfate1K573LC5TV7778-80-5OTYBMLCTZGSZBG-UHFFFAOYSA-L
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
K Lyte Cl PwrPowder, for solution1.86 gOralBristol Labs Division Of Bristol Myers Squibb1965-12-311997-08-14Canada
Polycitra-KSolution398 mgOralJanssen Pharmaceuticals1996-12-312009-10-02Canada
Polycitra-KPowder1.193 gOralAlza1996-12-312001-08-01Canada
Potassium AcetateInjection, solution, concentrate3.93 g/20mLIntravenousHospira, Inc.1984-07-20Not applicableUs
Potassium AcetateInjection, solution, concentrate196.3 mg/mLIntravenousHospira, Inc.1984-07-20Not applicableUs
Potassium AcetateLiquid392 mgIntravenousSandoz Canada Incorporated1988-12-312016-10-24Canada
Potassium Acetate Inj 2meq/mlSolution2 meqIntravenousAbbott1984-12-312008-06-06Canada
Potassium Acetate Inj 392mg/ml USPLiquid392 mgIntravenousLyphomed, Division Of Fujisawa Canada Inc.1984-12-311996-09-10Canada
Potassium Acetate InjectionSolution392 mgIntravenousFresenius Kabi1984-12-31Not applicableCanada
Potassium Acetate Injection USPLiquid39.2 %IntravenousOmega Laboratories Ltd2016-07-18Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Potassium AcetateInjection, solution, concentrate3.93 g/20mLIntravenousExela Pharma Sciences, Llc.2016-01-07Not applicableUs
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Complexed Potassium Tablets - 99mgTablet99 mgOralAlbion1996-09-062002-07-12Canada
K Lyte Tab Lime & Orange FlavTablet, effervescent975 mgOralBristol Labs Division Of Bristol Myers Squibb1965-12-311997-08-14Canada
Port A Mins Super Potassium 99Tablet99 mgOralGreat Earth Companies, Inc.1998-08-252002-10-02Canada
Potassium 250Capsule250 mgOralSeroyal International Inc.1997-12-122009-07-06Canada
Potassium 99 - CapletTablet99 mgOralHealth Wise Nutrition Inc.1995-12-312002-07-18Canada
Potassium 99mg TabletsTablet99 mgOralBioforce Canada Inc.1994-12-311997-04-14Canada
Potassium Gluconate Tab 550mg USPTablet92 mgOralPharmavite1991-12-312000-08-24Canada
Potassium Gluconate Tablets 99mg USPTablet99 mgOralRoyal Bodycare Canada Inc.1992-12-312001-08-07Canada
Potassium RougierLiquid780 mgOralRougier Pharma Division Of Ratiopharm Inc1965-12-312001-09-05Canada
Potassium Tab 99mgTablet99 mgOralRheingold Food International Ltd.1985-12-312007-07-26Canada
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
24 Multivitamins + MineralsPotassium (15 mg) + Beta carotene (10000 unit) + Biotin (25 mcg) + Calcium (130 mg) + Cholecalciferol (400 unit) + Choline bitartrate (25 mg) + Chromium (20 mcg) + Copper (1 mg) + Cyanocobalamin (25 mcg) + Folic Acid (.8 mg) + Inositol (25 mg) + Ferrous fumarate (15 mg) + Magnesium (65 mg) + Manganese (2 mg) + Molybdenum (20 mcg) + Niacin (25 mg) + Calcium pantothenate (25 mg) + Potassium Iodide (.1 mg) + Pyridoxine hydrochloride (25 mg) + Racemethionine (25 mg) + Riboflavin (25 mg) + Selenium (20 mcg) + Thiamine hydrochloride (25 mg) + Vanadium (20 mcg) + Vitamin A palmitate (5000 unit) + Vitamin C (150 mg) + Vitamin E (50 unit) + Zinc (10 mg)TabletOralStanley Pharmaceuticals, A Division Of Vita Health Products Inc.1997-04-302002-07-31Canada
AlphaligoPotassium (112.5 mg) + Cyanocobalamin (10 mcg) + Magnesium (119 mg) + Manganese (4.5 mg) + Sodium phosphate (125 mg)TabletOralClinique Lafontaine Inc, Division Les Importations Ortho1998-03-062008-08-07Canada
AminosynPotassium acetate (128 mg/100mL) + Glycine (448 mg/100mL) + Histidine (105 mg/100mL) + L-Alanine (448 mg/100mL) + L-Arginine (343 mg/100mL) + L-Isoleucine (252 mg/100mL) + L-Leucine (329 mg/100mL) + L-Lysine acetate (252 mg/100mL) + L-Phenylalanine (154 mg/100mL) + L-Proline (300 mg/100mL) + L-Threonine (182 mg/100mL) + L-Tryptophan (56 mg/100mL) + L-Tyrosine (31 mg/100mL) + L-Valine (280 mg/100mL) + Magnesium acetate (21 mg/100mL) + Methionine (140 mg/100mL) + Phosphoric acid (40 mg/100mL) + Serine (147 mg/100mL) + Sodium Chloride (234 mg/100mL)Injection, solutionIntravenousHospira, Inc.2011-03-23Not applicableUs
Aminosyn 3.5% MPotassium acetate (128 mg) + Glycine (448 mg) + Histidine (105 mg) + L-Alanine (448 mg) + L-Arginine (343 mg) + L-Isoleucine (252 mg) + L-Leucine (329 mg) + L-Lysine acetate (252 mg) + L-Phenylalanine (154 mg) + L-Proline (300 mg) + L-Threonine (182 mg) + L-Tryptophan (56 mg) + L-Tyrosine (31 mg) + L-Valine (280 mg) + Magnesium acetate (21 mg) + Methionine (140 mg) + Serine (147 mg) + Sodium Chloride (234 mg)LiquidIntravenousAbbott1980-12-311999-08-09Canada
Aqua-S SupplementPotassium (20 mg) + Pyridoxine hydrochloride (4 mg)TabletOralGarden State NutritionalsNot applicableNot applicableCanada
B 6 PlusPotassium (50 mg) + Magnesium (50 mg) + Niacin (20 mg) + Pyridoxine (50 mg) + Riboflavin (2.4 mg) + Thiamine (10 mg)TabletOralAnabolic Laboratories Inc.1967-12-312004-03-15Canada
BseltzerPotassium (330 mg) + Calcium (1000 mg) + Folic Acid (0.4 mg) + Magnesium (400 mg) + Vitamin C (60 mg) + Vitamin D (400 unit) + Zinc (15 mg)Granule, effervescentOralAbundance Marketing Ltd.2001-11-112007-07-23Canada
Buffered Vitamin C Powder With Ca Mg and KPotassium (19.8 mg) + Calcium (70 mg) + Magnesium (70 mg) + Vitamin C (470 mg)PowderOralThorne Research Inc.1997-04-182005-06-21Canada
Buffered Vitamin C Pwr W Cal-mag-potassiumPotassium (15 mg) + Calcium (68.25 mg) + Magnesium (34.42 mg) + Magnesium (4.21 mg) + Vitamin C (359.55 mg)PowderOralSisu Inc.1987-12-312009-08-04Canada
C-1000 Plus Zinc & PotassiumPotassium (12 mg) + Potassium (13 mg) + Calcium ascorbate (1 g) + Zinc (5 mg)TabletOralNu Life Nutrition Ltd.1987-12-312005-03-15Canada
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Hyperlyte CRPotassium acetate (1.96 g/20mL) + Calcium Chloride (.37 g/20mL) + Magnesium chloride (.51 g/20mL) + Sodium Chloride (1.17 g/20mL) + Sodium acetate (.68 g/20mL)Injection, solution, concentrateIntravenousB. Braun Medical Inc.2012-04-12Not applicableUs
NutrilytePotassium acetate (34.5 mg/mL) + Calcium Acetate (22 mg/mL) + Sodium gluconate (55 mg/mL) + Magnesium acetate (43 mg/mL) + Potassium Chloride (125 mg/mL) + Sodium acetate (135 mg/mL)Injection, solution, concentrateIntravenousAmerican Regent1990-09-302018-03-15Us
Nutrilyte IIPotassium acetate (98 mg/mL) + Calcium Chloride (16.55 mg/mL) + Magnesium chloride (25.5 mg/mL) + Sodium Chloride (74.5 mg/mL) + Sodium acetate (64.6 mg/mL)Injection, solution, concentrateIntravenousAmerican Regent1990-10-012017-07-26Us
Nutrilyte IIPotassium acetate (98 mg/mL) + Calcium Chloride (16.55 mg/mL) + Magnesium chloride (25.5 mg/mL) + Sodium Chloride (74.5 mg/mL) + Sodium acetate (64.6 mg/mL)Injection, solution, concentrateIntravenousAmerican Regent1990-10-012017-07-26Us
Potassium AcetatePotassium acetate (196 mg/mL)Injection, solutionIntravenousAmerican Regent1990-09-302017-12-22Us
Potassium AcetatePotassium acetate (392 mg/mL)Injection, solution, concentrateIntravenousAmerican Regent1990-09-302017-07-21Us
PurigoPotassium (9.3 g/100mL) + Calcium Carbonate (18 g/100mL) + Silicon dioxide (31 g/100mL)LiquidTopicalSun Jin Yu Ji Co2017-08-01Not applicableUs
Categories
UNII
RWP5GA015D
CAS number
7440-09-7
Weight
Average: 39.0983
Monoisotopic: 38.96370649
Chemical Formula
K
InChI Key
ZLMJMSJWJFRBEC-UHFFFAOYSA-N
InChI
InChI=1S/K
IUPAC Name
potassium
SMILES
[K]

Pharmacology

Indication

Potassium is used to regulate hypokalemia as a primary condition or secondary to other medical conditions.

Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action

Potassium is the major cation (positive ion) inside animal cells, while sodium is the major cation outside animal cells. The concentration differences of these charged particles causes a difference in electric potential between the inside and outside of cells, known as the membrane potential. The balance between potassium and sodium is maintained by ion pumps in the cell membrane. The cell membrane potential created by potassium and sodium ions allows the cell generate an action potential—a "spike" of electrical discharge. The ability of cells to produce electrical discharge is critical for body functions such as neurotransmission, muscle contraction, and heart function. Potassium is also an essential mineral needed to regulate water balance, blood pressure and levels of acidity.

TargetActionsOrganism
USodium/potassium-transporting ATPase subunit alpha-1Not AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination

Mostly urine but also skin and feces.

Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
PathwayCategory
Pyruvate MetabolismMetabolic
Indapamide Action PathwayDrug action
Trichlormethiazide Action PathwayDrug action
Amiloride Action PathwayDrug action
Rabeprazole Action PathwayDrug action
Alprenolol Action PathwayDrug action
Quinidine Action PathwayDrug action
Lidocaine (Antiarrhythmic) Action PathwayDrug action
Tocainide Action PathwayDrug action
Ibutilide Action PathwayDrug action
Methylenetetrahydrofolate Reductase Deficiency (MTHFRD)Disease
Diltiazem Action PathwayDrug action
Lesch-Nyhan Syndrome (LNS)Disease
Labetalol Action PathwayDrug action
Verapamil Action PathwayDrug action
Amlodipine Action PathwayDrug action
Nimodipine Action PathwayDrug action
Levobupivacaine Action PathwayDrug action
Oxymorphone Action PathwayDrug action
Fentanyl Action PathwayDrug action
Fluoxetine Action PathwayDrug action
Nicotine Action PathwayDrug action
Spermidine and Spermine BiosynthesisMetabolic
Lactose DegradationMetabolic
Myoadenylate deaminase deficiencyDisease
Pyruvate kinase deficiencyDisease
Levorphanol Action PathwayDrug action
Anileridine Action PathwayDrug action
Methadyl Acetate Action PathwayDrug action
Buprenorphine Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcemetacinThe therapeutic efficacy of Potassium can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Potassium.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Potassium.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Potassium.Illicit
AmilorideThe risk or severity of hyperkalemia can be increased when Potassium is combined with Amiloride.Approved
BenazeprilPotassium may increase the hyperkalemic activities of Benazepril.Approved, Investigational
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Potassium.Experimental, Illicit, Withdrawn
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Potassium.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Potassium.Approved, Illicit, Vet Approved
Candesartan cilexetilThe risk or severity of hypotension can be increased when Candesartan cilexetil is combined with Potassium.Approved
CandoxatrilPotassium may increase the hyperkalemic activities of Candoxatril.Experimental
Canrenoic acidThe risk or severity of hyperkalemia can be increased when Potassium is combined with Canrenoic acid.Approved, Withdrawn
CanrenoneThe risk or severity of hyperkalemia can be increased when Potassium is combined with Canrenone.Investigational
CaptoprilPotassium may increase the hyperkalemic activities of Captopril.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Potassium.Illicit, Investigational, Vet Approved
CilazaprilPotassium may increase the hyperkalemic activities of Cilazapril.Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Potassium.Approved, Illicit
DelaprilPotassium may increase the hyperkalemic activities of Delapril.Experimental
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Potassium.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Potassium.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Potassium.Approved, Investigational
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Potassium.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Potassium.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Potassium.Experimental, Illicit
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Potassium.Approved, Illicit
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Potassium.Experimental
DrospirenoneThe risk or severity of hyperkalemia can be increased when Potassium is combined with Drospirenone.Approved
EnalaprilPotassium may increase the hyperkalemic activities of Enalapril.Approved, Vet Approved
EnalaprilatPotassium may increase the hyperkalemic activities of Enalaprilat.Approved
EplerenoneThe risk or severity of hyperkalemia can be increased when Potassium is combined with Eplerenone.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Potassium.Approved, Illicit
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Potassium.Illicit, Vet Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Potassium.Approved, Illicit, Investigational, Vet Approved
FosinoprilPotassium may increase the hyperkalemic activities of Fosinopril.Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Potassium.Approved, Illicit, Investigational
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Potassium.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Potassium.Approved, Illicit
ImidaprilPotassium may increase the hyperkalemic activities of Imidapril.Investigational
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Potassium.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Potassium.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Potassium.Approved
LisinoprilPotassium may increase the hyperkalemic activities of Lisinopril.Approved, Investigational
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Potassium.Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Potassium.Experimental
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Potassium.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Potassium.Approved, Illicit
MoexiprilPotassium may increase the hyperkalemic activities of Moexipril.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Potassium.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Potassium.Approved
NicomorphineThe risk or severity of adverse effects can be increased when Nicomorphine is combined with Potassium.Experimental
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Potassium.Approved, Illicit
OmapatrilatPotassium may increase the hyperkalemic activities of Omapatrilat.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Potassium.Approved, Illicit
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Potassium.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Potassium.Approved, Investigational, Vet Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Potassium.Approved, Vet Approved
PerindoprilPotassium may increase the hyperkalemic activities of Perindopril.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Potassium.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Potassium.Experimental
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Potassium.Experimental
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Potassium.Approved, Investigational
QuinaprilPotassium may increase the hyperkalemic activities of Quinapril.Approved, Investigational
RamiprilPotassium may increase the hyperkalemic activities of Ramipril.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Potassium.Approved
RescinnaminePotassium may increase the hyperkalemic activities of Rescinnamine.Approved
Sodium phosphatePotassium may increase the nephrotoxic activities of Sodium phosphate.Approved
SpiraprilPotassium may increase the hyperkalemic activities of Spirapril.Approved
SpironolactoneThe risk or severity of hyperkalemia can be increased when Potassium is combined with Spironolactone.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Potassium.Approved, Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Potassium.Approved
TemocaprilPotassium may increase the hyperkalemic activities of Temocapril.Experimental, Investigational
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Potassium.Experimental
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Potassium.Approved, Investigational
TrandolaprilPotassium may increase the hyperkalemic activities of Trandolapril.Approved
TriamtereneThe risk or severity of hyperkalemia can be increased when Potassium is combined with Triamterene.Approved
ZofenoprilPotassium may increase the hyperkalemic activities of Zofenopril.Experimental
Food Interactions
Not Available

References

Synthesis Reference

John B. Sardisco, "Production of potassium sulfate and hydrogen chloride." U.S. Patent US4045543, issued 1865.

US4045543
General References
Not Available
External Links
PubChem Compound
5462222
PubChem Substance
46506517
ChemSpider
4575326
ChEBI
26216
PharmGKB
PA451047
Wikipedia
Potassium
ATC Codes
C03BB07 — Clofenamide and potassiumC03AB04 — Chlorothiazide and potassiumC03AB02 — Hydroflumethiazide and potassiumC03CB02 — Bumetanide and potassiumC03AB03 — Hydrochlorothiazide and potassiumC03AB07 — Cyclopenthiazide and potassiumC03AB06 — Trichlormethiazide and potassiumC03AB05 — Polythiazide and potassiumC03CB01 — Furosemide and potassiumC03BB04 — Chlortalidone and potassiumB05XA17 — Potassium acetateC03BB03 — Clopamide and potassiumC03AB01 — Bendroflumethiazide and potassiumC03AB08 — Methyclothiazide and potassiumC03AB09 — Cyclothiazide and potassiumC03BB02 — Quinethazone and potassiumC03BB05 — Mefruside and potassium
AHFS Codes
  • 88:29.00* — Minerals
  • 40:12.00 — Replacement Preparations
FDA label
Download (632 KB)
MSDS
Download (72.2 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingTreatmentOsteomyelitis1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedTreatmentHigh Blood Pressure (Hypertension)1
1RecruitingTreatmentStroke, Ischemic1
1, 2CompletedSupportive CareHigh Blood Pressure (Hypertension) / Pre-Hypertension1
2CompletedPreventionBMI >30 kg/m2 / Cardiovascular Disease (CVD) / Heart Diseases / High Blood Pressure (Hypertension) / Vascular Diseases1
2CompletedTreatmentBorderline Hypokalemia1
2CompletedTreatmentHyperglycemias / Strokes1
3CompletedTreatmentLeukemias1
3RecruitingTreatmentCardiac Arrythmias1
3RecruitingTreatmentHealthy Volunteers1
4Enrolling by InvitationDiagnosticColonoscopy1
4Unknown StatusTreatmentAcute Hypokalemia1
Not AvailableCompletedBasic ScienceBlood Pressures / High Blood Pressure (Hypertension) / Renal Function / Vascular Function1
Not AvailableCompletedScreeningOther Diseases or Conditions1
Not AvailableCompletedTreatmentType 2 Diabetes Mellitus1
Not AvailableCompletedTreatmentType 2 Diabetes Mellitus / Vascular Diseases1
Not AvailableRecruitingTreatmentCorneal Opacity1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • American Regent
  • Hospira Inc.
  • Luitpold Pharmaceuticals Inc.
Dosage forms
FormRouteStrength
Injection, solutionIntravenous
CapsuleOral
TabletOral
Tablet, extended releaseOral
PowderOral
Powder, for solutionOral1.86 g
Tablet, effervescentOral975 mg
Tablet, effervescentOral
SolutionIntravenous
LiquidIntravenous
Granule, effervescentOral
Injection, solution, concentrateIntravenous
PowderOral1.193 g
SolutionOral398 mg
CapsuleOral250 mg
Injection, solutionIntravenous196 mg/mL
Injection, solution, concentrateIntravenous196.3 mg/mL
Injection, solution, concentrateIntravenous3.93 g/20mL
Injection, solution, concentrateIntravenous392 mg/mL
SolutionIntravenous2 meq
LiquidIntravenous392 mg
SolutionIntravenous392 mg
LiquidIntravenous39.2 %
TabletOral92 mg
TabletOral99 mg
LiquidOral780 mg
LiquidTopical
KitOral
Solution, concentrateOral
LiquidOral
Powder, for solutionOral
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6946149No2003-03-072023-03-07Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)63.38 °CNot Available
boiling point (°C)770°CNot Available
water solubilitySolubleNot Available
Predicted Properties
PropertyValueSource
logP0.2ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count0ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area0 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity0 m3·mol-1ChemAxon
Polarizability1.78 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of inorganic compounds known as homogeneous alkali metal compounds. These are inorganic compounds containing only metal atoms,with the largest atom being a alkali metal atom.
Kingdom
Inorganic compounds
Super Class
Homogeneous metal compounds
Class
Homogeneous alkali metal compounds
Sub Class
Not Available
Direct Parent
Homogeneous alkali metal compounds
Alternative Parents
Not Available
Substituents
Homogeneous alkali metal
Molecular Framework
Not Available
External Descriptors
alkali metal atom (CHEBI:26216)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Steroid hormone binding
Specific Function
This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates th...
Gene Name
ATP1A1
Uniprot ID
P05023
Uniprot Name
Sodium/potassium-transporting ATPase subunit alpha-1
Molecular Weight
112895.01 Da
References
  1. Silva E, Gomes P, Soares-da-Silva P: Overexpression of Na(+)/K (+)-ATPase parallels the increase in sodium transport and potassium recycling in an in vitro model of proximal tubule cellular ageing. J Membr Biol. 2006;212(3):163-75. Epub 2007 Feb 28. [PubMed:17334838]
  2. Li C, Geering K, Horisberger JD: The third sodium binding site of Na,K-ATPase is functionally linked to acidic pH-activated inward current. J Membr Biol. 2006;213(1):1-9. Epub 2007 Mar 8. [PubMed:17347782]
  3. Stanely Mainzen Prince P, Karthick M: Preventive effect of rutin on lipids, lipoproteins, and ATPases in normal and isoproterenol-induced myocardial infarction in rats. J Biochem Mol Toxicol. 2007;21(1):1-6. [PubMed:17366541]
  4. Simon WA, Herrmann M, Klein T, Shin JM, Huber R, Senn-Bilfinger J, Postius S: Soraprazan: setting new standards in inhibition of gastric acid secretion. J Pharmacol Exp Ther. 2007 Jun;321(3):866-74. Epub 2007 Mar 16. [PubMed:17369284]
  5. Iannello S, Milazzo P, Belfiore F: Animal and human tissue Na,K-ATPase in normal and insulin-resistant states: regulation, behaviour and interpretative hypothesis on NEFA effects. Obes Rev. 2007 May;8(3):231-51. [PubMed:17444965]

Drug created on June 30, 2007 12:13 / Updated on May 22, 2018 23:51